IBM Micromedex IV Comp.

IBM Micromedex IV Comp. app is free to subscribers of IBM Micromedex IV Comp. online.

When multiple IV medications are combined, the risk of complication is very real. Efficacy of one or more drugs can be reduced or a potentially dangerous incompatibility can occur. With this app you will have access to the largest, most comprehensive IV compatibility resource which:

• Enhances patient safety by pinpointing potentially dangerous combinations
• Helps clinicians interpret conflicting compatibility results by identifying contributing factors such as the physical compatibility, storage, study period, container and chemical stability
• Includes drug-solution compatibility results as well as drug-drug compatibility results when creating an admixture or administering via Y-Site.

IBM Micromedex IV Comp. is a reliable resource for on-the-go access to the industry’s most trusted clinical reference information, providing users with more informed treatment decisions at the point of care. An internet connection is not required, allowing you to make decisions with confidence at anytime, from anywhere.

Not sure if your institution subscribes to IBM Micromedex? Check with your Chief Medical Officer, Director of Pharmacy, Medical Librarian, or anyone else at your facility responsible for clinical reference information.

If the facility you work at subscribes to IBM Micromedex, follow these instructions to obtain a password:

1. Login to IBM Micromedex through your subscribing facility
2. Click “Download Center” near the top of the application
3. Refer to the detailed downloading instructions, which include your password for activating the application at no charge.

If you cannot locate the “Download Center” link please contact support to receive your password at https://developer.ibm.com/watsonhealth/micromedex-support/
Email Address: ProductSupport@Merative.com
Phone number: US and Canada 1.877.843.6796
Global : +1.303.354.4100 ,Press Option 2

Existing paid customers will continue to have access to the content going forward. Show More